Divestment

U3 Pharma

U3 Pharma developed monoclonal antibody therapies for cancer targeting receptor tyrosine kinases.

Responsible partner
News

Key Facts

Sector: Life Sciences
Country: Germany
Fund: LSP 3
Entry: 2006
Exit: 2011

Responsible Partner

Joachim Rothe

Joachim Rothe

Partner

News

January 12, 2026
EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases
January 12, 2026
EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics
October 22, 2025
EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics
October 22, 2025
EQT Life Sciences’ ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion

Do You Want to Know More?

We are eager to explore how we can achieve great things together.

U3 Pharma | EQT Portfolio